Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Urology ; 166: 164-169, 2022 08.
Article in English | MEDLINE | ID: mdl-35561850

ABSTRACT

OBJECTIVE: To describe local recurrence rates and patient-reported outcomes when Mohs micrographic surgery with cytokeratin-7 immunostains (MMS-CK7) is included in the interdisciplinary management of extramammary Paget's disease (EMPD) METHODS: A retrospective study was conducted of EMPD treated with MMS-CK7 as part of an interdisciplinary team at an academic medical center between 2009 and 2016. Local recurrence rates and patient-reported outcomes were determined by record review and patient surveys. RESULTS: Twenty tumors in 19 patients were treated using MMS-CK7. After MMS-CK7 defined clear microscopic margins, 75% (15/20) of tumors underwent excision or reconstruction by a surgical colleague. Internal malignancy screening was performed by multiple specialties in 17 patients, with 1 associated malignancy of prostate cancer detected. No local recurrence was detected with a mean follow-up of 75.2 months. Most patients were satisfied with appearance (18/19, 95%) and function (16/19, 84%) after surgery. CONCLUSION: Interdisciplinary teams that include MMS-CK7 can treat EMPD with low local recurrence rates, high patient satisfaction, and thorough internal malignancy screening.


Subject(s)
Mohs Surgery , Paget Disease, Extramammary , Frozen Sections , Humans , Keratin-7 , Male , Margins of Excision , Neoplasm Recurrence, Local/pathology , Paget Disease, Extramammary/diagnosis , Paget Disease, Extramammary/surgery , Retrospective Studies
4.
J Am Acad Dermatol ; 77(2): 333-340.e1, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28711085

ABSTRACT

BACKGROUND: Positive or equivocal margins after wide local excision (WLE) complicate surgical management of cutaneous melanoma. OBJECTIVE: To identify the frequency of and risk factors for positive or equivocal margins after WLE of cutaneous melanoma. METHODS: Retrospective, single-center, cross-sectional study of 1345 consecutive melanomas treated with WLE. RESULTS: The overall frequency of positive or equivocal margins was 4.2% (56/1345), ranging from 2.2% to 22.6%, depending on the size of the surgical margins, patient characteristics, biopsy history, and the clinicopathology of the melanoma. In descending order, independent risk factors associated with the greatest odds for positive or equivocal margins after multivariate analysis were noncompliance with recommended surgical margins (odds ratio [OR] 5.57, P = .002); anatomic location on the head, neck, hands, feet, genitals, or pretibial leg (OR 5.07, P < .001); histologic regression (OR 2.78, P = .007); in situ melanoma (OR 2.27, P = .011); multiple biopsies at the tumor site before WLE (OR 1.92 [per biopsy], P = .004); and increasing age (OR 1.049 [per year], P < .001). LIMITATIONS: This was a single-site, retrospective observational study. CONCLUSIONS: Clinicopathologic factors, especially location in cosmetically or functionally sensitive areas and noncompliance with recommended surgical margins, identified melanomas at increased risk for positive or equivocal margins after WLE.


Subject(s)
Head and Neck Neoplasms/surgery , Melanoma/surgery , Skin Neoplasms/surgery , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Cross-Sectional Studies , Foot , Genitalia , Guideline Adherence , Hand , Humans , Leg , Margins of Excision , Melanoma/pathology , Middle Aged , Neoplasm, Residual , Practice Guidelines as Topic , Retrospective Studies , Risk Factors , Skin Neoplasms/pathology , Young Adult
5.
J Am Acad Dermatol ; 77(2): 341-348, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28601390

ABSTRACT

BACKGROUND: Detecting a more advanced stage of the primary melanoma after wide local excision and reconstruction can complicate patient counseling about prognosis, management of surgical margins, and indications for sentinel lymph node biopsy. OBJECTIVE: To identify the frequency of and risk factors associated with upstaging after wide local excision of primary melanoma. METHODS: Retrospective, single center, cross-sectional study of 1332 consecutive in situ to stage T4a melanomas treated with wide local excision. RESULTS: The overall rate of upstaging of melanoma was 3.9% (52/1332). After multivariate analysis, the greatest risk factor for upstaging was anatomic location on the head, neck, hands, feet, genitals, or pretibial leg (odds ratio [OR] 7.06, P < .001) followed by extension of the melanoma to the base of the biopsy specimen (OR 3.42, P < .001); the need for multiple preoperative scouting biopsies (OR 1.89, P = .004); older age (OR 1.03 per year, P = .002); and nonlentigo maligna histologic subtype (OR 3.6, P = .002). LIMITATIONS: This was a single-site, retrospective observational study. CONCLUSIONS: Clinicopathologic characteristics, particularly anatomic location on the head, neck, hands, feet, genitals, or pretibial leg and subtotal diagnostic biopsies, identify melanomas with an increased risk for upstaging.


Subject(s)
Head and Neck Neoplasms/pathology , Melanoma/pathology , Skin Neoplasms/pathology , Skin/pathology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Biopsy , Cross-Sectional Studies , Female , Foot , Genitalia , Hand , Head and Neck Neoplasms/surgery , Humans , Leg , Male , Margins of Excision , Melanoma/surgery , Middle Aged , Neoplasm Staging , Neoplasm, Residual , Retrospective Studies , Risk Factors , Skin Neoplasms/surgery , Young Adult
6.
Diabetes ; 65(10): 3151-60, 2016 10.
Article in English | MEDLINE | ID: mdl-27411381

ABSTRACT

It remains uncertain whether recurrent nonsevere hypoglycemia (Hypo) results in long-term cognitive impairment in type 1 diabetes (T1D). This study tested the hypothesis that specifically in the T1D state, Hypo leads to cognitive impairment via a pathological response to oxidative stress. Wild-type (Control) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) null mice were studied. Eight groups of mice (Control and Nrf2(-/-) ± T1D and ± Hypo) were subject to recurrent, twice-weekly, insulin or saline injections over 4 weeks, after which cognitive function was assessed and brain tissue analyzed. Recurrent moderate hypoglycemia in T1D, but not Control, mice significantly impaired cognitive performance, and this was associated with hippocampal oxidative damage and inflammation despite an enhanced expression of Nrf2 and its target genes Hmox1 and Nqo1 In Nrf2(-/-) mice, both T1D and Hypo independently resulted in impaired cognitive performance, and this was associated with oxidative cell damage and marked inflammation. Together, these data suggest that Hypo induces an Nrf2-dependent antioxidant response in the hippocampus, which counteracts oxidative damage. However, in T1D, this neuroprotective mechanism is insufficient to prevent neuronal oxidative damage, resulting in chronic deficits in working and long-term memory.


Subject(s)
Cognitive Dysfunction/physiopathology , Diabetes Mellitus, Type 1/metabolism , Hypoglycemia/metabolism , Hypoglycemia/physiopathology , Animals , Cognitive Dysfunction/metabolism , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , Hippocampus/immunology , Hippocampus/metabolism , Inflammation/metabolism , Lipid Peroxidation/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , NF-E2-Related Factor 2/genetics , NF-E2-Related Factor 2/metabolism , Oxidative Stress/physiology , Polymerase Chain Reaction , Random Allocation
8.
PLoS One ; 9(8): e103451, 2014.
Article in English | MEDLINE | ID: mdl-25084162

ABSTRACT

Few studies have been conducted specifically on the dense connective tissue located in the posterior medial part of the cervical epidural space. This study was undertaken to examine the presence of this connection between the cervical dura mater and the posterior wall of spinal canal at the level of C1-C2. 30 head-neck specimens of Chinese adults were used. Gross dissection was performed on the suboccipital regions of the 20 specimens. Having been treated with the P45 plastination method, 10 specimens were sliced (9 sagittal and 1 horizontal sections). As a result, a dense fibrous band was identified in the nuchal ligament of 29 specimens (except for one horizontal section case). This fascial structure arose from the tissue of the posterior border of the nuchal ligament and then projected anteriorly and superiorly to enter the atlantoaxial interspace. It was termed as to be named ligament (TBNL). In all 30 specimens the existence of a fibrous connection was found between the posterior aspect of the cervical dura mater and the posterior wall of the spinal canal at the level of the atlas to the axis. This fibrous connection was identified as vertebrodural ligament (VDL). The VDL was mainly subdivided into three parts, and five variations of VDL were identified. These two structures, TBNL and VDL, firmly link the posterior aspect of cervical dura mater to the rear of the atlas-axis and the nuchal region. According to these findings, the authors speculated that the movements of the head and neck are likely to affect the shape of the cervical dural sleeve via the TBNL and VDL. It is hypothesized that the muscles directly associated with the cervical dural sleeve, in the suboccipital region, may work as a pump providing an important force required to move the CSF in the spinal canal.


Subject(s)
Cerebrospinal Fluid/physiology , Cervical Vertebrae/anatomy & histology , Ligaments, Articular/anatomy & histology , Ligaments/anatomy & histology , Epidural Space , Female , Humans , Male
9.
Proc Natl Acad Sci U S A ; 107(50): 21830-5, 2010 Dec 14.
Article in English | MEDLINE | ID: mdl-21098287

ABSTRACT

Hyperphosphorylated tau plays an important role in the formation of neurofibrillary tangles in brains of patients with Alzheimer's disease (AD) and related tauopathies and is a crucial factor in the pathogenesis of these disorders. Though diverse kinases have been implicated in tau phosphorylation, protein phosphatase 2A (PP2A) seems to be the major tau phosphatase. Using murine primary neurons from wild-type and human tau transgenic mice, we show that the antidiabetic drug metformin induces PP2A activity and reduces tau phosphorylation at PP2A-dependent epitopes in vitro and in vivo. This tau dephosphorylating potency can be blocked entirely by the PP2A inhibitors okadaic acid and fostriecin, confirming that PP2A is an important mediator of the observed effects. Surprisingly, metformin effects on PP2A activity and tau phosphorylation seem to be independent of AMPK activation, because in our experiments (i) metformin induces PP2A activity before and at lower levels than AMPK activity and (ii) the AMPK activator AICAR does not influence the phosphorylation of tau at the sites analyzed. Affinity chromatography and immunoprecipitation experiments together with PP2A activity assays indicate that metformin interferes with the association of the catalytic subunit of PP2A (PP2Ac) to the so-called MID1-α4 protein complex, which regulates the degradation of PP2Ac and thereby influences PP2A activity. In summary, our data suggest a potential beneficial role of biguanides such as metformin in the prophylaxis and/or therapy of AD.


Subject(s)
Metformin/pharmacology , Neurofibrillary Tangles/metabolism , Protein Phosphatase 2/metabolism , TOR Serine-Threonine Kinases/metabolism , tau Proteins/metabolism , Adenylate Kinase/metabolism , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Animals , Cells, Cultured , Enzyme Inhibitors/pharmacology , Epitopes , HeLa Cells , Humans , Hypoglycemic Agents/pharmacology , Mechanistic Target of Rapamycin Complex 1 , Mice , Mice, Transgenic , Multiprotein Complexes , Neurofibrillary Tangles/pathology , Neurons/cytology , Neurons/metabolism , Okadaic Acid/pharmacology , Phosphorylation , Protein Phosphatase 2/genetics , Proteins/metabolism , Signal Transduction/drug effects , TOR Serine-Threonine Kinases/genetics , tau Proteins/genetics
10.
J Biol Chem ; 285(44): 33747-55, 2010 Oct 29.
Article in English | MEDLINE | ID: mdl-20801881

ABSTRACT

The Keap1/Nrf2/ARE pathway controls a network of cytoprotective genes that defend against the damaging effects of oxidative and electrophilic stress, and inflammation. Induction of this pathway is a highly effective strategy in combating the risk of cancer and chronic degenerative diseases, including atherosclerosis and neurodegeneration. An acetylenic tricyclic bis(cyano enone) bearing two highly electrophilic Michael acceptors is an extremely potent inducer in cells and in vivo. We demonstrate spectroscopically that both cyano enone functions of the tricyclic molecule react with cysteine residues of Keap1 and activate transcription of cytoprotective genes. Novel monocyclic cyano enones, representing fragments of rings A and C of the tricyclic compound, reveal that the contribution to inducer potency of the ring C Michael acceptor is much greater than that of ring A, and that potency is further enhanced by spatial proximity of an acetylenic function. Critically, the simultaneous presence of two cyano enone functions in rings A and C within a rigid three-ring system results in exceptionally high inducer potency. Detailed understanding of the structural elements that contribute to the reactivity with the protein sensor Keap1 and to high potency of induction is essential for the development of specific and selective lead compounds as clinically relevant chemoprotective agents.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Cytoskeletal Proteins/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , NAD(P)H Dehydrogenase (Quinone)/metabolism , Animals , Cell Line, Tumor , Cells, Cultured , Female , Humans , Kelch-Like ECH-Associated Protein 1 , Mice , Models, Chemical , NF-E2-Related Factor 2/metabolism , Neurodegenerative Diseases/metabolism , Oxidative Stress
11.
J Trauma ; 66(6): 1591-7; discussion 1598, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19509619

ABSTRACT

BACKGROUND: Cerebral contusions contain numerous leukocytes, and a temporal relationship exists among cerebral chemokine expression, leukocyte recruitment, and contusion enlargement. This would suggest a role for chemokines in contusion development. However, it has not been established if serum concentrations of chemokines such as interleukin-8 (IL-8) or monocyte chemoattractant protein-1 (MCP-1) change with contusion enlargement. METHODS: Eighteen adult patients with severe contusional traumatic brain injury, on computerized tomography, were identified. Patients with diffuse injuries or extradural and subdural hematomas associated with mass effect were not included in the study. Daily serum samples were taken for the measurement of IL-8 and MCP-1 concentrations for up to 11 days postinjury. RESULTS: In the patients who died while in intensive care, IL-8 and MCP-1 were significantly greater than in those patients discharged (18 [0-202] vs. 0 [0-156] pg/mL and 498 [339-1,063] vs. 368 [86-11,289] pg/mL for IL-8 and MCP-1, respectively). No difference was seen in serum chemokine levels in patients who deteriorated with contusion enlargement compared with those that did not. The IL-8 and MCP-1 concentrations did not change significantly over time either in the group as a whole or in the subgroup of patients who deteriorated. CONCLUSIONS: These inflammatory mediators may be predictive of a poor outcome in patients with traumatic brain injury in which contusions are the predominant abnormality. However, they do not distinguish those patients who will deteriorate because of contusion enlargement.


Subject(s)
Brain Injuries/blood , Brain Injuries/complications , Chemokine CCL2/blood , Interleukin-8/blood , Adult , Aged , Brain Injuries/etiology , Disease Progression , Female , Humans , Male , Middle Aged , Young Adult
13.
J Neurotrauma ; 26(4): 507-25, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19210118

ABSTRACT

The expression of the neutrophil chemokine macrophage inflammatory protein-2 (MIP-2/CXCL2) and the monocyte chemokine monocyte chemotactic protein-1 (MCP-1/CCL2) have been described in glial cells in vitro but their origin following TBI has not been established. Furthermore, little is known of the modulation of these chemokines. Chemokine expression was investigated in male Sprague-Dawley rats following moderate lateral fluid percussion injury (LFPI). At 0, 4, 8, 12, and 24 h after injury, brains were harvested and MIP-2/CXCL2 and MCP-1/CCL2 levels measured by ELISA. To investigate the inhibition of chemokine expression a second cohort of animals received dexamethasone (1-15mg/kg), FK506 (1mg/kg), or vehicle, systemically, immediately after injury. These animals were sacrificed at the time of peak chemokine expression. A third cohort of animals was also sacrificed at the time of peak chemokine expression and immunohistochemistry performed for MIP-2/CXCL2 and MCP-1/CCL2. Following LFPI, chemokines were increased in the ipsilateral hemisphere, MIP-2/CXCL2 peaking at 4 h and MCP-1/CCL2 peaking at 8-12 h post-injury. Dexamethasone significantly reduced cortical MCP-1/CCL2, but not MIP-2/CXCL2 concentrations. FK506 did not inhibit chemokine expression. In undamaged brain, chemokine expression was localized to cells with a neuronal morphology. For MIP-2/CXCL2 this was supported by double staining for the neuronal antigen NeuN. In contused tissue, increased MIP-2/CXCL2 and MCP-1/CCL2 staining was visible in cells with the morphology of degenerating neurons. MIP-2/CXCL2 and MCP-1/CCL2 are increased after injury, and neurons appear to be the source of this expression. Chemokine expression was selectively inhibited by dexamethasone. The implications of this are discussed.


Subject(s)
Brain Injuries/immunology , Brain Injuries/metabolism , Brain/immunology , Brain/metabolism , Chemokine CCL2/metabolism , Chemokine CXCL2/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Brain/drug effects , Brain Injuries/drug therapy , Chemokine CCL2/analysis , Chemokine CCL2/drug effects , Chemokine CXCL2/analysis , Chemokine CXCL2/drug effects , DNA-Binding Proteins , Dexamethasone/pharmacology , Disease Models, Animal , Down-Regulation/drug effects , Down-Regulation/immunology , Immunosuppressive Agents/pharmacology , Male , Nerve Degeneration/drug therapy , Nerve Degeneration/immunology , Nerve Degeneration/metabolism , Nerve Tissue Proteins/analysis , Nerve Tissue Proteins/metabolism , Neurons/cytology , Neurons/immunology , Neurons/metabolism , Nuclear Proteins/analysis , Nuclear Proteins/metabolism , Rats , Rats, Sprague-Dawley , Tacrolimus/pharmacology , Time Factors , Up-Regulation/drug effects , Up-Regulation/immunology
14.
Neurobiol Aging ; 30(9): 1430-43, 2009 Sep.
Article in English | MEDLINE | ID: mdl-18242780

ABSTRACT

Patients with Mild Cognitive Impairment (MCI), exhibiting both working memory and olfactory deficits are likely to progress to Alzheimer's disease (AD). Targeting this pre-clinical AD population with disease modifying agents or cognitive enhancers represents the best strategy for halting or delaying the impact of this pernicious disease. However, there is a paucity of animal models of MCI with which to assess putative therapeutic strategies. We describe an odour span task which assesses the ability of mice to remember lists of odours, and report subtle cognitive deficits in human amyloid over-expressing (Tg2576) mice, at an age prior to plaque deposition. Four-month-old Tg2576 mice exhibited normal acquisition and performance in the standard 12-span task, but were significantly impaired when memory load was increased to 22 odours. By 8-months, a performance deficit was apparent in the 12-span task and by 1-year mice also exhibited significant acquisition deficits. Thus, by assessing olfactory working memory in Tg2576 mice we can model aspects of MCI in rodents and aid development of future therapeutic strategies for AD.


Subject(s)
Cognition Disorders/physiopathology , Memory Disorders/physiopathology , Memory, Short-Term/physiology , Smell/genetics , Alzheimer Disease/genetics , Alzheimer Disease/physiopathology , Alzheimer Disease/psychology , Amyloid beta-Protein Precursor/genetics , Animals , Cognition Disorders/genetics , Cognition Disorders/psychology , Disease Models, Animal , Disease Progression , Humans , Learning Disabilities/genetics , Learning Disabilities/physiopathology , Male , Memory Disorders/genetics , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neuropsychological Tests , Odorants
15.
Apoptosis ; 13(3): 394-403, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18214681

ABSTRACT

The molecular chaperone nucleophosmin has been identified as a novel Bax binding protein with this interaction proposed to be a key event in the activation and translocation of Bax in mitochondrial dysfunction and apoptotic cell death. Using a proximity assay, we have quantitatively defined the high affinity and saturable interaction between Bax and nucleophosmin indicative of a competitive and specific mechanism. Binding of full length Bax to nucleophosmin was only observed after conformational change was induced using non-ionic detergents (e.g., NP-40). The Bax-nucleophosmin interaction was inhibited by a Bax C-terminal antibody (IC(50) = 1 nM) but minimally affected by antibodies directed against either the N-terminus or alpha-helices 4 and 5. Bcl-2 and p53 inhibited the interaction between full length activated Bax and nucleophosmin. The proximity assay based on the Bax-nucleophosmin interaction was robust and reproducible (Z' = 0.50) facilitating its use for screening a small chemical library. A low molecular weight non-peptide compound, 2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)ethanohydrazide, partially inhibited the Bax-nucleophosmin interaction (IC(50) = 100 nM) and also attenuated UV-induced cell death of HEK293 cells. The present investigations demonstrate the importance of exposure of the C-terminus of Bax for its interaction with nucleophosmin. These protein-protein interaction assays provide a technical approach both for the study of Bax-interacting proteins and for the discovery of novel anti-apoptotic agents.


Subject(s)
Apoptosis/drug effects , Nuclear Proteins/metabolism , bcl-2-Associated X Protein/metabolism , Amino Acid Sequence , Antibodies/pharmacology , Apoptosis/radiation effects , Cells, Cultured , Humans , Hydrazines/pharmacology , Molecular Chaperones/metabolism , Nucleophosmin , Protein Binding , Protein Conformation/drug effects , Protein Interaction Mapping , Thiazoles/pharmacology , Ultraviolet Rays , bcl-2-Associated X Protein/immunology
16.
Proteomics ; 7(17): 3085-96, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17676660

ABSTRACT

Apoptosis contributes to cell death after cerebral ischaemia. A quantitative proteomics approach has been employed to define alterations in protein levels in apoptosis induced with staurosporine (STS). Human neuroblastoma derived SH-SY5Y cells were treated with STS (500 nM for 6 h) to induce apoptosis. Quantitative 2-DE was used to determine the changing protein levels with MALDI-TOF MS identification of proteins. Of the 154 proteins analysed, 13 proteins were significantly altered as a result of the apoptotic stimulus; ten of the proteins showed an increase in level with STS and were identified as heat shock cognate 71 (Hsc71), two isoforms of heat shock protein 70 (Hsp70), glucose regulated protein 78 (GRP78), F-actin capping protein, stress-induced phosphoprotein 1, chromatin assembly factor 1 (CAF-1), protein disulphide isomerase A3 (PDI A3) precursor, transitional ER ATPase and actin interacting protein 1 (AIP 1). Three proteins which displayed significant decrease in levels with STS were identified as tubulin, vimentin and glucose regulated protein 94 (GRP94). The functional roles and subcellular locations of these proteins collectively indicate that STS-induced apoptosis provokes induces an unfolded protein response involving molecular chaperones, cochaperones and structural proteins indicative of ER stress.


Subject(s)
Apoptosis/drug effects , Endoplasmic Reticulum/metabolism , Heat-Shock Proteins , Molecular Chaperones/metabolism , Proteomics/methods , Staurosporine/pharmacology , Cell Line, Tumor , Electrophoresis, Gel, Two-Dimensional , Endoplasmic Reticulum Chaperone BiP , Humans , Membrane Potential, Mitochondrial/physiology , Mitochondria/physiology , Molecular Chaperones/genetics , Neuroblastoma/pathology , Peptide Mapping , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
17.
Pharmacol Ther ; 115(2): 292-306, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17599430

ABSTRACT

Nerve growth factor (NGF) and other members of the neurotrophin family are critical for the survival and differentiation of neurons and have been implicated in the pathophysiology of numerous disease states. Although the therapeutic potential of neurotrophins has generated much excitement over the past decade, inconvenient pharmacokinetics and adverse side-effect profiles have limited the clinical usefulness of neurotrophic factors themselves. Compounds that mimic neurotrophin signaling and overcome the pharmacokinetic and side-effect barriers may have greater therapeutic potential. Here, we review the progress to date of clinical trials with direct neurotrophin modulators and describe alternative strategies to target (modulate) neurotrophin production and/or their signal transduction pathways. Particular emphasis is placed on small molecules that are able to modulate neurotrophin function in diseases of the nervous system. These alternative strategies show promise in preclinical studies, with some advancing into clinical development. Moreover, the recognition that clinically effective therapeutics, such as antidepressants and immunophilin ligands, can modulate neurotrophin function suggests that the concept of small molecule therapeutics that promote neurotrophic function may still be viable.


Subject(s)
Nerve Growth Factors/physiology , Receptors, Nerve Growth Factor/drug effects , Amyotrophic Lateral Sclerosis/drug therapy , Amyotrophic Lateral Sclerosis/metabolism , Animals , Brain-Derived Neurotrophic Factor/biosynthesis , Brain-Derived Neurotrophic Factor/physiology , Brain-Derived Neurotrophic Factor/therapeutic use , Depression/drug therapy , Depression/metabolism , Humans , Nerve Growth Factor/biosynthesis , Nerve Growth Factor/physiology , Nerve Growth Factor/therapeutic use , Nerve Growth Factors/biosynthesis , Nerve Growth Factors/therapeutic use , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/metabolism , Obesity/drug therapy , Obesity/metabolism , Peripheral Nervous System Diseases/drug therapy , Peripheral Nervous System Diseases/metabolism , Receptors, Nerve Growth Factor/physiology , Signal Transduction , Spinal Cord Injuries/drug therapy , Spinal Cord Injuries/metabolism , Wound Healing/drug effects
18.
J Inflamm (Lond) ; 4: 5, 2007 Mar 16.
Article in English | MEDLINE | ID: mdl-17367517

ABSTRACT

The inflammatory process, orchestrated against a variety of injurious stimuli, is composed of three inter-related phases; initiation, propagation and resolution. Understanding the interplay between these three phases and harnessing the beneficial properties of inflammation whilst preventing its damaging effects, will undoubtedly lead to the advent of much needed therapies, particularly in chronic disease states. The P2X7 receptor (P2X7R) is increasingly recognised as an important cell surface regulator of several key inflammatory molecules including IL-1beta, IL-18, TNF-alpha and IL-6. Moreover, as P2X7R-dependent cytokine production is driven by activating the inflammasome, antagonists of this receptor are likely to have therapeutic potential as novel anti-inflammatory therapies. The function of the P2X7R in inflammation, immunity and its potential role in disease will be reviewed and discussed.

19.
Neuropharmacology ; 52(2): 590-7, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17101156

ABSTRACT

Positive allosteric modulation of AMPA receptor function has therapeutic potential in a number of psychiatric disorders and neurodegenerative diseases. AMPA receptor potentiators can induce neurite sprouting in vivo. Using a strategy of combined morphological and biochemical analyses, we investigated the effect of the AMPA receptor potentiator LY404187 on neurite growth in the SH-SY5Y human neuroblastoma cell line. LY404187 (0.1-10 microM) increased average neurite length and neurofilament expression when co-administered with s-AMPA. Co-incubation with s-AMPA and LY404187 also increased Trk receptor expression. All actions of LY404187 were sensitive to AMPA receptor blockade by the selective antagonist CNQX (10 microM). Antibody sequestration of BDNF attenuated neurite growth following AMPA receptor potentiator administration, suggesting that LY404187 increases neurite length in vitro by a BDNF mediated mechanism. AMPA receptor potentiation activates multiple intracellular neurochemical cascades and the present report identifies BDNF as one key mediator of the neurotrophic effects of AMPA receptor potentiation.


Subject(s)
Gene Expression Regulation/physiology , Neurites/physiology , Receptors, AMPA/physiology , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Antibodies/pharmacology , Brain-Derived Neurotrophic Factor/immunology , Cell Line, Tumor , Dose-Response Relationship, Drug , Drug Interactions , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Gene Expression Regulation/drug effects , Humans , Neurites/drug effects , Neuroblastoma/pathology , Neurofilament Proteins/genetics , Neurofilament Proteins/metabolism , Receptor, trkA/metabolism , Sulfonamides/pharmacology , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology
20.
Eur Neuropsychopharmacol ; 17(2): 145-55, 2007 Jan 15.
Article in English | MEDLINE | ID: mdl-16650968

ABSTRACT

alpha7-Nicotinic acetylcholine receptors (alpha7-nAChR) have been implicated in a range of cognitive deficits in schizophrenia. Therefore we examined alpha7-nAChR knockout (KO), heterozygote (HT) and wildtype (WT) littermate mice in the 5-CSR (a rodent model of sustained attention) and odour span (a novel mouse working memory paradigm) tasks, and related performance to nAChR density. Whilst there was no difference between groups in baseline 5-CSR task performance, alpha7-nAChR KO's exhibited significantly higher omission levels compared to WT mice on increasing the attentional load, with HT mice performing at an intermediate level. Furthermore, alpha7-nAChR KO mice were significantly impaired in the odour span task when compared to WT mice, in a pattern consistent with impaired attention. These behavioural deficits were associated with the loss of alpha7-nAChRs, as alpha4beta2-nAChR density was unaltered in these mice. Thus these studies intimate that the attentional impairment in alpha7-nAChR transgenic mice maybe core to other deficits in cognition.


Subject(s)
Attention Deficit Disorder with Hyperactivity/etiology , Cognition Disorders/complications , Receptors, Nicotinic/deficiency , Aconitine/analogs & derivatives , Aconitine/pharmacokinetics , Alkaloids/pharmacokinetics , Animals , Animals, Newborn , Attention Deficit Disorder with Hyperactivity/genetics , Azocines/pharmacokinetics , Behavior, Animal , Choice Behavior/physiology , Cognition Disorders/genetics , Dose-Response Relationship, Drug , Mice , Mice, Knockout , Nicotinic Antagonists/pharmacokinetics , Protein Binding/drug effects , Quinolizines/pharmacokinetics , Reaction Time/genetics , Receptors, Nicotinic/physiology , Tritium/pharmacokinetics , alpha7 Nicotinic Acetylcholine Receptor
SELECTION OF CITATIONS
SEARCH DETAIL
...